2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow MEDI4736 monotherapy: new trials by email Literature Review of MEDI4736 monotherapy trials Research Report on MEDI4736 monotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma MEDI4736 monotherapy, tremelimumab+MEDI4736 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | AstraZeneca | 65 | 2015-11-16 | 2018-08-02 |
| Study of Tremelimumab in Patients With Advanced Solid Tumors Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy - Urothelial Bladder Cancer, Triple-negative Breast Cancer | Phase 2 | Completed | AstraZeneca | 64 | 2015-11-02 | 2023-11-15 |
Anophthalmia with pulmonary hypoplasia (1) · Triple Negative Breast Neoplasms (1)
AstraZeneca (2)
Netherlands (2) · South Korea (2) · United States (2) · Belgium (1) · Canada (1) · Germany (1) · Poland (1) · Spain (1)
Eileen M O'Reilly, M.D (1) · Sharma Padmanee, MD, PhD (1)
2015 (1)